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Introduction
Malignant melanoma (MM) of the skin is a life-threatening disease of the skin. The incidence as well as mortality rates are increasing since years. 1 In 2012, there have been approximately 87 000 cases of melanoma treated in the European Union (EU) and the member states of the European Free Trade Association (EFTA). 2 Exposition to ultraviolet (UV) radiation and a sunburn history are known to be the main exogenous risk factor in the development of melanoma skin cancer. 3 The increase in incidence is often explained by a changed leisure-time behaviour, which is associated with a higher level of UV exposure. 4 Artificial UV radiation is also discussed to favour the development of skin cancer. [5] [6] [7] [8] According to Boniol et al., 9 an amount of 1-11% of melanoma cases is attributable to sunbed use. To prevent melanoma skin cancer attributable to sunbed use, the European Code of Practice for Artificial Tanning was developed and signed by 10 countries (Belgium, Cyprus, Czech Republic, Denmark, Finland, Germany, Hungary, Latvia, the Netherlands, Poland). 10 It contains recommendations on reference values concerning the maximal irradiance, advising sunbed user by trained staff and prohibition of sunbed use for minors. Few European countries have implemented age regulations by law. 11, 12 These regulations already
show first results in Germany with a steep decrease of sunbed use since 2009. 13 However, since there is a considerable time shift between UV exposure and the occurrence of melanoma, the consequences of sunbed use decrease will become obvious not until the next decades. Hence, in the next years Europe will have to deal with a further increasing incidence and associated costs-of-illness, which are even supposed to rise with the availability of more new high pricing treatment options. So far, cost-of-illness studies are available only for a few European countries. The aim of this study was therefore to model the cost-of-illness (COI) of melanoma in the EU and the EFTA states based on the incidence approach and to estimate the costs of melanoma attributable to sunbed use.
Materials and methods

Data sources
Several sources are used to determine the COI of MM.
Data on population were taken from the World Bank. 14 The epidemiological information on the incidence of MM for each country is taken from the International Agency for Research on Cancer. 2 Where no epidemiological information for 2012 was available, data for the most recent year were taken for analysis.
To estimate the treatment costs of MM a systematic literature research in Medline/PubMed was conducted. Methodology and results of the review are reported elsewhere. 15 Additional data sources were used for the economic model on COI:
• Information on the national gross domestic product (GDP) was taken from World Bank. 14 • Information on the national health expenditures (HE) was taken from United Nations Statistics Division. 16 • Information on the gross national income (GNI) and the income development was taken from the World Bank. 14 
Economic model on COI
While information on cost-of-illness per patient of MM was found for few countries only, we developed a model for imputation of cost data to estimate COI for all European countries.
We assumed a relationship between the direct medical costs of MM, the GDP and the HE in our model. [17] [18] [19] [20] [21] [22] [23] [24] Where no direct costs for the treatment of MM were found in literature, we calculated treatment costs weighting the cost information from other countries with the national GDP and HE. 18, 19, [24] [25] [26] [27] [28] [29] The calculation of indirect costs is limited to morbidity costs. It was based on the assumption of a relation between absent days from work due to morbidity and the GNI. Where no information on morbidity costs for MM was available, we calculated indirect costs weighting the cost information from other countries with the national GNI. where GNI, gross national income; GPD, gross domestic product; HE, health expenditures; k, countries with available information; u, countries without information. An adjustment for the national purchasing power parity (PPP) was carried out to allow a reliable comparison of costs between countries. The PPP is used to eliminate international differences in prices. The price levels are harmonized by adjusting the prices for a defined basket of identical goods in several countries. As a result, the price differences occurring from divergences in the economic situation of the countries diminish. 30 Finally, we multiplied the number of incident cases with the costs per patient for the treatment of MM to estimate COI for the European countries.
The most conservative costing approach, that should be used therefore, was identified to be present in calculations based on publications including all stages of MM. 15 Most publications transferring direct costs into other countries are based on calculations using the GDP. We conducted also analysis based on national HE because this approach seems to provide the most accurate results. Therefore, we carried out the analysis of direct costs based on both, the GDP and the HE. Real direct costs are supposed to be in the cost range resulting from these two approaches. Analysis of indirect costs was based on the GNI only.
The incidence is defined as the number of new melanoma cases arising in 2012. Therefore, all persons diagnosed with a melanoma who died for any reasons in 2012 are included in the incidence. Since it is unknown how many persons with an incident melanoma died in each country in 2012 mortality costs are not included.
Economic model on costs attributable to sunbed use
Information on fraction of MM caused by sunbed use was obtained from the meta-analysis published by Boniol et al. 9 focusing on the burden of MM due to sunbed use in Europe. For Cyprus and Malta, which were not included in the meta-analysis, prevalence data for Spain, Greece, Italy and Portugal were used. For the eastern European countries, we assumed the average attributable fraction of all included countries. We estimated HE caused by sunbed use by multiplying the number of incident cases and the national cost-of-illness per patient with the incidence fraction attributable to sunbed use. Examples of modelling total costs per patient attributable to sunbed use based on the GDP (blue) and national total costs attributable to sunbed use based on HE adjusted on PPP (grey) are illustrated in Fig. 1 .
Sensitivity analysis
We conducted a sensitivity analysis by extrapolation of direct costs based on the GDP per capita as well as on the HE per capita. Real direct costs are supposed to lie between the cost ranges resulting from the two approaches.
Results
Characterization of epidemiology and national economic data
The countries included in this analysis show huge variations in the population size as well as in the economic performance ( Table 1) . The national population was ranging from 320 700 to 80.4 million inhabitants. This has a strong impact on the number of annual incident cases per country varying between 36 and 16 884 cases and therefore on the national costs for MM. The cost-of-illness of MM is also affected by the economic performance of countries, which can be measured by the GDP per capita (€ 5709-€ 82 517), the HE per capita (€ 342-€ 5446) or the GNI per capita (€ 4768-€ 62 566).
Direct costs for MM care
Using the raw data, unadjusted for the PPP, direct costs for the first year after initial MM diagnosis range between € 833 per patient treated in Bulgaria and € 11 901 in Luxembourg when calculations are based on the GDP (Table 1) . Direct national costs vary between € 89 719 in Malta and € 84.0 million in Germany and result in € 387 million for all member states of the EU and the EFTA ( Table 2) . Figure 1 Economic model -example for modelling costs attributable to sunbed use based on the gross domestic product, health expenditures and the gross national income. GDP, gross domestic product; GNI, gross national income; HE, health expenditures; p.p., per patient; PPP, purchasing power parity.
When these estimates are based on HE, the lowest average costs per patient treated result for Romania (€ 476) and the highest for Denmark (€ 10 793; Table 1 ). National direct costs for melanoma treatment vary between € 78 894 in Malta and € 91.7 million in Germany. Here direct costs for all included countries sum up to € 394.6 million ( Table 2) .
Both approaches show very similar costs. The calculation based on the HE results in slightly higher costs. However, in countries with a higher share of the GDP spend on HE, cost estimations based on the GDP are lower compared to the approach based on the HE.
Indirect costs for MM
Morbidity costs are strongly related to the GNI per capita, with a few exceptions. They range between € 126 in Sweden and € 5472 per patient in the UK (Table 1) . On a national level, these costs are lowest in Malta (€ 37 867) and highest in the UK (€ 79.0 million). Total morbidity costs account for € 208.6 million.
Total costs of MM
Total costs of MM for all of the 31 countries range between € 597.5 and € 603.2 million, including direct and indirect COI. Direct costs for melanoma treatment amount for 60-80% of COI on average regardless of the approach chosen. The lowest share of direct costs is present in the UK (42%), the largest share is spent in Denmark and Sweden (94-96%). When estimations are based on the HE approach direct costs amount for <50% of total costs in Croatia, Estonia, Latvia, Poland, Romania and Slovakia additionally.
Total costs per patient adjusted for PPP
After adjusting MM treatment costs for the PPP differences between countries diminished. Calculations based on the GDP result in direct costs per patient between € 1829 in Bulgaria and € 10 215 in Luxembourg (Fig. 2) . Costs due to morbidity range from € 102 per patient in Sweden to € 5178 in the UK. Average weighted annual direct and indirect costs per patient amount for For countries that entered the EU since the year 2004, in particular countries in the east and southeast of Europe, HE remain a lot lower even after adjustment for PPP.
Total national costs adjusted for PPP
For the calculation of national costs for the first year of MM treatment beside the costs per patient, additionally the population size and the incidence have to be taken into account. In combination, these variables can mutually reinforce each other. Therefore, countries with high costs per patient (for instance Luxembourg) may result in comparatively low national costs while countries with average costs per patient (for instance Germany) may result in extremely high national cost.
Based on GDP, total national costs range between € 172 236 in Malta and € 126.5 million in the UK. When estimations are based on HE total national costs range between € 157 703 in Malta and € 128.0 million in Germany.
Cost-of-illness is highest in countries with a high population (>40 million inhabitants). Here, national costs vary between € 26 million in Spain and € 128 million in Germany (Table 3) . Accordingly, lowest national costs were found in countries with a small population (<3 million) ranging from € 157 703 in Malta to € 2.2 million in Slovenia. COI for melanoma was more expensive in western and northern European countries. Even after adjusting for the PPP, COI for these 16 out of 31 included countries accounts for 89% of total costs. The role of sunbed use
The attributable fraction of melanoma cases was reported by Boniol et al. 9 to vary in the 18 described countries above between 0.4% and 6.5% for men and 1.3-10.6% for women. In total, in 2012 approximately 4450 new cases of melanoma have been induced by sunbed use in the EU and the EFTA states, which corresponds to 5.1% of all incident melanoma cases. Due to the national differences in attributable fraction of melanoma caused by sunbed use, the differences in incidence and cost per patient, the attributable melanoma cost range from € 1570 in Malta to € 11.1 million in Germany (Table 4) .
Total COI for MM attributable to sunbed use for the 31 countries sums up to an amount of € 32.5-€ 33.4 million. Only little differences consist between calculations based on HE and the GDP. Treatment costs for melanoma attributable to sunbed use are much higher in women than in men. Annual direct costs are about € 21.7-€ 22.4 million for women and € 10.8-€ 11.1 million for men (Table 4) .
Total costs attributable to sunbed use adjusted for PPP
Adjusting national melanoma treatment costs attributable to sunbed use for the PPP and using the reported national incidence, expenses are still many times higher in Germany compared to other countries, followed by the UK, the Netherlands, Denmark, France and Switzerland. Sunbed use induces melanoma costs of € 30.2-€ 32.7 million in the EU and the EFTA states, which corresponds to 5.3-5.8% of total melanoma costs (Table 5) .
National costs range from € 1757 in Malta to € 11.0 million in Germany. Compared to the COI of melanoma in general, differences between countries are larger in COI attributable to sunbed use. The fraction of melanoma attributable to sunbed use is high (women >8%, men >5%) in countries with a high GDP per capita (>€ 30 000) and high HE per capita (>€ 3000) after adjusting for PPP. Therefore, countries with high costs per patient have higher costs attributable to sunbed use whereas countries with low costs per patient result in lower costs attributable to sunbed use.
Discussion
Sunbed use has been proven to favour the development of skin cancer. [7] [8] [9] The economic impact of MM attributable to sunbed use in Europe is an important issue in preventive, political and Cost-of-illness of melanoma health economic considerations. However, the presented results are based on a model estimating the economic effects and should be interpreted and used with caution. We found a significant economic burden caused by melanoma, of which a relevant share is attributable to sunbed use resulting in approximately 4450 incident cases per year and costs of more than € 30 million within the first year of initial diagnosis.
Previous articles report melanoma incidence rates to be lower in eastern European countries, melanomas are thicker at diagnosis and thus mortality is higher before 1992. 31 Looking at the current data, we assume that not much has changed about the late diagnosis in eastern European countries while the incidence is still comparatively low but the mortality high. 2 Hence, indirect costs in eastern European countries are supposed to be considerable higher if mortality costs were included.
In the prevalence of sunbed use, a north-to-south gradient was observed in some studies within Europe indicating a more popular use in northern countries due to little natural sunlight. 32, 33 In contrast, a multinational Euromelanoma study found sunbed use was to be above 30% in Belgium, Luxembourg, Hungary, Italy and Spain. 34 The reported fraction of COI attributable to artificial radiation used in present study was highest in Belgium and Luxembourg, but also in Denmark, Austria, Germany and the Netherlands (8.5-10.8%), whereas in Italy and Spain it was lowest in whole Europe (<1.0%). 9 Potential reasons for these differences can lie in the predominance of darker skin types in the south of Europe, the time shift between exposition to UV radiation and the occurrence of melanoma skin cancer or in a selection bias in the recruitment of study participants. A health economic analysis concerning COI of melanoma found 8974 (5176 invasive and 3771 in situ) cases of melanoma attributable to sunbed use in the United States in 2015 resulting in annual treatment costs of US$ 5054 per patient and total direct costs of US$ 45.2 million. 35 Indirect costs were calculated additionally based on the GPD resulting in US$ 3523 million. Waters et al. used the prevalence approach which enabled also the consideration of mortality costs. Cost-of-illness in our model amounts for € 4458 per patient. Taking into account that the reference year in our study is 2012 and therefore 3 years earlier and only drugs and therapies that entered the market until 2008 could be considered, the differences between the study from Waters et al. and our study are small.
Limitations
The comparison of outcomes from different countries is challenging due to different cutaneous phototypes, natural UV exposure, health system structures, legal requirements considering registration of skin cancer cases and access restrictions for sunbed use as well as complex interrelations of influencing factors. Beside these challenges, the current study has some limitations.
• Stages of melanoma
We did not differentiate between stages of melanoma in our model because information on the incidence of melanoma by stages was not available for all included countries.
• Incidence of melanoma We obtained the incidence of melanoma from the International Agency of Research on Cancer, which collects epidemiological information from the countries. We cannot exclude that these countries may have divergent reporting guidelines or physicians may show divergent adherence to guidelines which leads to deviations between reported and actual incidence.
• Morbidity costs Since no information on the age of melanoma patients was available, we could not distinguish between retired patients and patients of working age. Therefore, we calculated morbidity costs for all persons, independently of age.
• Cost-of-illness studies
The model used in the current study is based on a systematic review on cost-of-illness studies from a societal perspective. In this review, only five studies analysing the COI for all stages of melanoma in at least one of the relevant countries could be identified and included. 15 All of the studies took place in western or northern Europe. A larger number of studies and a higher diversity of countries serving as calculation basis could increase the reliability of our results. Cost-of-illness of melanoma
Conclusion
Taking these limitations into account, all costs are reported in ranges consisting of costs modelled on the GDP and on HE. This article provides a first estimation on cost-of-melanoma in Europe, although only a few studies exist which focus on cost-of-illness. To get a more precise definition of national cost-of-illness for melanoma and cost attributable to sunbed use, further studies are needed. However, we could show that cost-of-illness of MM in the included countries is significant and melanoma induced by tanning devices is a relevant factor. Since publication of the included articles in 2000-2008 new treatment options, in particularly costly drugs, were approved in Europe. Although we adjusted all costs for the price level of 2012, we could not take into account the increase in costs due to new and expensive treatment options that entered the market in the last years. Therefore, it may be expected that treatment costs of melanoma in Europe have increased in the last few years. We also tend to underestimate COI because we could not consider any mortality costs. Skin cancer, in first line attributable to sunbed use, could be easily prevented while avoiding indoor tanning by increasing awareness and legal regulation.
